The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Hosted on MSN1mon
FDA approves BMS’ Opdivo Qvantig for solid tumour indicationsThis new combination product, which includes nivolumab co-formulated ... with Opdivo plus Yervoy (ipilimumab) combination regimen, or along with chemotherapy or cabozantinib.
Erratum: Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial Supported in part ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback